Compound for the antemortem diagnosis of Alzheimer's Disease and in vivo imaging and prevention of amyloid deposition
US6114175A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 9, 1998 |
| Grant date | Sep 5, 2000 |
| Priority date | — |
| Expiry date | Nov 9, 2018 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2821
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Amyloid binding compounds which are non-azo derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized by amyloidosis, such as Down's Syndrome are described. Pharmaceutical compositions containing non-azo derivatives of Chrysamine G and methods using such compositions to prevent cell degeneration and amyloid-induced toxicity in amyloidosis associated conditions are also described. Methods using non-azo Chrysamine G derivatives to stain or detect amyloid deposits in biopsy or post-mortem tissue are also described. Methods using non-azo Chrysamine G derivatives to quantify amyloid deposits in homogenates of biopsy and post-mortem tissue are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.